Albany, NY -- (SBWIRE) -- 02/19/2019 -- Methicillin-resistant Staphylococcus aureus Market and Epidemiology report

18 Feb. 19

The prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) isolates in intensive care units in the United States is 60 per cent, and more than 90,000 invasive infections due to MRSA occurred in the United States.

1. There is approximately 170,000 methicillin-resistant Staphylococcus aureus (MRSA) infections in European healthcare systems each year, causing more than 5000 fatalities and more than 1 million additional inpatient days.
2. MRSA is responsible for horse infections in France, of the total patient population, greater than 5% were confirmed to be MRSA.
3. MRSA prevalence among strains of S. aureus found to be nearly 45% in a Japanese community hospital.

(Albany, US) DelveInsight launched Methicillin-resistant Staphylococcus aureus market report

Key topics covered

1. The MRSA market report provides an in-depth analysis of the disease overview and the comprehensive details about MRSA treatment algorithms and treatment guidelines in the US, Europe, and Japan.
2. This Methicillin-resistant Staphylococcus aureus market report provides insights about the historical and current patient pool and forecasted trend for 7 major markets.
3. Methicillin-resistant Staphylococcus aureus market report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs.
4. MRSA market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market.

Request for sample pages

"The prevalence of MRSA patients in hospitals, rehabilitation centres and nursing homes of a rural district in Germany reported less than 5%."

Currently, the market size is dominated by several antibacterial agents which include cephalosporin, glycycycline, glycopeptides and lipoglycopeptides, lipopeptide, oxazolidinones. Glycopeptides and lipoglycopeptides including Dalvance, Vibativ and Vancomycin and many other marketed antibiotics demonstrates potent activity against MRSA and are used to treat invasive HA-MRSA infections in the U.S. However, the recent approvals of Orbactiv, Dalvance, and Sivextro have greatly increased treatment options for MRSA infections, making the hospital-treated MRSA market highly competitive.

Still, there are some unmet medical needs for the treatment with Vancomycin, as it becomes less susceptible to this agent among S. aureus along with the emergence of non-susceptible MRSA strains and inadequate poor source control of foci of infection. Thus, treatment options for persistent MRSA bacteremia or bacteremia having more advantage over Vancomycin include daptomycin, ceftaroline, and combination therapies.

To summarize, a better and clear understanding of the pathogenesis of Methicillin-resistant Staphylococcus aureus (MRSA) will significantly improve the treatment regimens and development of novel therapies. With this, several companies have started working towards the development of new therapeutic options. The Methicillin-resistant Staphylococcus aureus (MRSA) market is expected to experience a positive growth in the coming years owing to the already prescribed products along with the launch of distinctive emerging therapies in the coming years.

Methicillin-resistant Staphylococcus aureus (MRSA) Companies covered
1. Basilea Pharmaceutica
2. CrystalGenomics
3. Savara Pharmaceuticals
4. MicuRx Pharmaceuticals
And many others

Methicillin-resistant Staphylococcus aureus (MRSA) Drugs covered
1. Ceftobiprole
2. CG400549
3. AeroVanc
4. Contezolid Acefosamil
And many others

Methicillin-resistant Staphylococcus aureus (MRSA) Table of contents
1. Methicillin-resistant Staphylococcus aureus (MRSA) Report Introduction
2. Methicillin-Resistant Staphylococcus aureus: Market Overview at a Glance
3. Methicillin-resistant Staphylococcus aureus (MRSA) Disease Background and Overview
4. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology and Patient Population
4.1. Methicillin-resistant Staphylococcus aureus (MRSA) Key Findings
4.2. Methicillin-resistant Staphylococcus aureus (MRSA) Population and Forecast Parameters
4.3. Methicillin-resistant Staphylococcus aureus (MRSA) 7MM Prevalent Cases
4.4. Methicillin-resistant Staphylococcus aureus (MRSA) Total Patient Population by Regions
4.4.1. United States
4.4.2. EU5
4.4.2.1. Assumptions & Rationale
4.4.2.2. Germany
4.4.2.3. France
4.4.2.4. Italy
4.4.2.5. Spain
4.4.2.6. United Kingdom
4.4.3. Japan
5. Current Treatment and Medical Practices
6. Current Unmet Needs
7. Methicillin-resistant Staphylococcus aureus (MRSA) Marketed drugs
7.1. List of Methicillin-resistant Staphylococcus aureus (MRSA) Marketed Drugs
7.2. Zyvox - Pfizer
7.3. Cubicin - Merck & Company
8. Methicillin-resistant Staphylococcus aureus (MRSA) Emerging Therapies
8.1. Methicillin-resistant Staphylococcus aureus (MRSA) Key Cross Competition
8.2. Ceftobiprole - Basilea Pharmaceutica
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. CG400549 - CrystalGenomics
8.4. Contezolid Acefosamil- MicuRx
9. Methicillin-Resistant Staphylococcus aureus: Market Outlook
10. Methicillin-resistant Staphylococcus aureus (MRSA) 7MM: Country-Wise Market Analysis (2017-2028)
10.1. United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. Italy Market Size
10.5. Spain Market Size
10.6. United Kingdom Market Size
10.7. Japan
11. Methicillin-resistant Staphylococcus aureus (MRSA) Market Drivers
12. Methicillin-resistant Staphylococcus aureus (MRSA) Market Barriers
13. Appendix
14. Report Methodology
14.1. Sources Used
15. DelveInsight Capabilities
16. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight